Search

Your search keyword '"Conti, Laura"' showing total 930 results
Start Over Author "Conti, Laura"
930 results on '"Conti, Laura"'

201. Detection and Differential Diagnosis of Prekallikrein Deficiency: Genetic Study of New Families and Systematic Review of the Literature

Author

Barco, Stefano, primary, Sollfrank, Stefanie, additional, Trinchero, Alice, additional, Tomao, Luigi, additional, Zieger, Barbara, additional, Kremer Hovinga, Johanna A., additional, Conti, Laura, additional, Adenäuer, Anke, additional, Miloni, Erwin, additional, Lackner, Karl J., additional, Rossmann, Heidi, additional, and Lammle, Bernhard, additional

Published
2018
Full Text
View/download PDF

202. AlmaWorld

Author

Conti, Laura, primary, Delnevo, Giovanni, additional, and Mirri, Silvia, additional

Published
2018
Full Text
View/download PDF

203. Cripto-1 Plasmid DNA Vaccination Targets Metastasis and Cancer Stem Cells in Murine Mammary Carcinoma

Author

Witt, Kristina, primary, Ligtenberg, Maarten A., additional, Conti, Laura, additional, Lanzardo, Stefania, additional, Ruiu, Roberto, additional, Wallmann, Tatjana, additional, Tufvesson-Stiller, Helena, additional, Chambers, Benedict J., additional, Rolny, Charlotte, additional, Lladser, Alvaro, additional, Lundqvist, Andreas, additional, Cavallo, Federica, additional, and Kiessling, Rolf, additional

Published
2018
Full Text
View/download PDF

204. GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer

Author

Pizzuti, Laura, Sergi, Domenico, Mandoj, Chiara, Antoniani, Barbara, Sperati, Francesca, Chirico, Andrea, Di Lauro, Luigi, Valle, Mario, Garofalo, Alfredo, Vizza, Enrico, Corrado, Giacomo, Tomao, Federica, Rinaldi, Massimo, Carpano, Silvia, Maugeri-Saccà, Marcello, Conti, Laura, Digiesi, Giovanna, Marchetti, Paolo, De Maria Marchiano, Ruggero, Giordano, Antonio, Barba, Maddalena, Carosi, Maria A., Vici, Patrizia, De Maria Marchiano, Ruggero (ORCID:0000-0003-2255-0583), Pizzuti, Laura, Sergi, Domenico, Mandoj, Chiara, Antoniani, Barbara, Sperati, Francesca, Chirico, Andrea, Di Lauro, Luigi, Valle, Mario, Garofalo, Alfredo, Vizza, Enrico, Corrado, Giacomo, Tomao, Federica, Rinaldi, Massimo, Carpano, Silvia, Maugeri-Saccà, Marcello, Conti, Laura, Digiesi, Giovanna, Marchetti, Paolo, De Maria Marchiano, Ruggero, Giordano, Antonio, Barba, Maddalena, Carosi, Maria A., Vici, Patrizia, and De Maria Marchiano, Ruggero (ORCID:0000-0003-2255-0583)

Abstract

In recent years, the poorly remarkable goals achieved in terms of patients’ important outcomes for ovarian cancer have fueled our interest toward the study of its metabolic roots. Within this research pipeline, we assessed the association between the expression of the glucose transporter GLUT1, as expressed at the tumor tissue level, and circulating pre-surgical levels of fasting glucose in a case series including data from 40 patients with high FIGO stage serous ovarian cancer. Patients who provided data to the current analysis were randomly selected from a larger cohort. To our purposes, the procedures related to serum and tissue collection, storage and biomarker assessment were highly standardized and centralized at the institutional laboratories. The GLUT1 antibody SPM498 SPRING (REF. E13810) was used at a 1:500 dilution in 2 µm slides. Staining for GLUT1 was observed at the cell membrane level in all the cases assessed, but strong staining was described in 29 (72.5%) of them. The agreement between the two independent reviewers was 100%. Strong GLUT1 staining was inversely associated with circulating levels of fasting glucose, with a particularly striking difference for patients in the lowest fasting glucose tertile (p = 0.044). These results support the biological plausibility of the association of interest. If confirmed in larger studies, our findings may help clarify the potentials of biomarkers related to energy metabolism in terms of prognosis definition, treatment assignment, and outcome interpretation for patients with high FIGO stage serous ovarian cancer.

Published
2018

205. Additional file 1: Figure S1. of Overexpression of syndecan-1, MUC-1, and putative stem cell markers in breast cancer leptomeningeal metastasis: a cerebrospinal fluid flow cytometry study

Author

Cordone, Iole, Masi, Serena, Summa, Valentina, Mariantonia Carosi, Vidiri, Antonello, Fabi, Alessandra, Pasquale, Alessia, Conti, Laura, Rosito, Immacolata, Carapella, Carmine, Villani, Veronica, and Pace, Andrea

Subjects
skin and connective tissue diseases
Abstract

Flow cytometry analysis of cerebospinal fluid (CSF) samples of patients with breast cancer leptomeningeal metastasis. Representative dot plot and histogram for CSF breast cancer cells and tumor-associated leukocytes. (PPTX 2013 kb)

Published
2017
Full Text
View/download PDF

207. Cross-sectional analysis of circulating tumor DNA in primary colorectal cancer at surgery and during post-surgery follow-up by liquid biopsy.

Author

Allegretti, Matteo, Cottone, Giuliano, Carboni, Fabio, Cotroneo, Ettore, Casini, Beatrice, Giordani, Elena, Amoreo, Carla Azzurra, Buglioni, Simonetta, Diodoro, Maria, Pescarmona, Edoardo, Zazza, Settimio, Federici, Orietta, Zeuli, Massimo, Conti, Laura, Cigliana, Giovanni, Fiorentino, Francesco, Valle, Mario, Giacomini, Patrizio, and Spinella, Francesca

Subjects
CIRCULATING tumor DNA, COLORECTAL cancer, PROCTOLOGY, ONCOLOGIC surgery, CROSS-sectional method
Abstract

Background: Liquid biopsy (LB) in early-stage, non-metastatic colorectal cancer (CRC) must be sensitive enough to detect extremely low circulating tumor DNA (ctDNA) levels. This challenge has been seldom and non-systematically investigated. Methods: Next generation sequencing (NGS) and digital PCR (dPCR) were combined to test tumor DNAs (tDNAs) and paired ctDNAs collected at surgery from 39 patients, 12 of whom were also monitored during the immediate post-surgery follow up. Patients treated for metastatic disease (n = 14) were included as controls. Results: NGS and dPCR concordantly (100% agreement) called at least one single nucleotide variant (SNV) in 34 tDNAs, estimated differences in allelic frequencies being negligible (±1.4%). However, despite dPCR testing, SNVs were only detectable in 15/34 (44.1%) ctDNAs from patients at surgery, as opposed to 14/14 (100%) metastatic patients. This was likely due to striking differences (average 10 times, up to 500) in ctDNA levels between groups. NGS revealed blood-only SNVs, suggesting spatial heterogeneity since pre-surgery disease stages, and raising the combined NGS/dPCR sensitivity to 58.8%. ctDNA levels at surgery correlated with neither tumor size, stage, grade, or nodal status, nor with variant abundance in paired tDNA. LB sensitivity reached 63.6% when ctDNA was combined with CEA. Finally, persistence and absence of ctDNA on the first conventional (month 3) post-surgery follow-up were associated with fast relapse and a disease-free status in 3 and 7 patients, respectively. Conclusions: A simple clinical NGS/dPCR/CEA combination effectively addresses the LB challenge in a fraction of non-metastatic CRC patients. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

208. Serum or plasma? An old question looking for new answers.

Author

Plebani, Mario, Banfi, Giuseppe, Bernardini, Sergio, Bondanini, Francesco, Conti, Laura, Dorizzi, Romolo, Ferrara, Fulvio Enrico, Mancini, Rita, and Trenti, Tommaso

Subjects
SERUM, PATHOLOGICAL laboratories, BLOOD coagulation factors
Abstract

Serum or plasma? An old question looking for new answers. There is a continual debate on what type of sample a clinical laboratory should use. While serum is still considered the gold standard and remains the required sample for some assays, laboratories must consider turn-around time, which is an important metric for laboratory performance and, more importantly, plays a critical role in patient care. In addition, a body of evidence emphasise the choice of plasma in order to prevent modifications of some analytes due to the coagulation process and related interferences. Advantages and disadvantages of serum and plasma are discussed on the basis of current literature and evidence. In addition, data are provided on the current utilisation of the samples (serum or plasma) in Italy and in other countries. Finally, a rationale for a possible switch from serum to plasma is provided. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

211. Bovine herpesvirus 4-based vector delivering the full length xCT DNA efficiently protects mice from mammary cancer metastases by targeting cancer stem cells

Author

Donofrio, Gaetano, primary, Tebaldi, Giulia, additional, Lanzardo, Stefania, additional, Ruiu, Roberto, additional, Bolli, Elisabetta, additional, Ballatore, Andrea, additional, Rolih, Valeria, additional, Macchi, Francesca, additional, Conti, Laura, additional, and Cavallo, Federica, additional

Published
2018
Full Text
View/download PDF

212. Abstract A77: Cripto-1 vaccination elicits protective immune response to metastatic breast cancer and breast cancer stem cells

Author

Witt, Kristina, primary, Ligtenberg, Maarten Alexander, additional, Conti, Laura, additional, Lanzardo, Stefania, additional, Ruiu, Roberto, additional, Tufvesson-Stiller, Helena, additional, Ostling, Jeanette, additional, Rolny, Charlotte, additional, Lladser, Alvaro, additional, Lundqvist, Andreas, additional, Cavallo, Federica, additional, and Kiessling, Rolf, additional

Published
2018
Full Text
View/download PDF

215. Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting

Author

Mandoj, Chiara, primary, Pizzuti, Laura, additional, Sergi, Domenico, additional, Sperduti, Isabella, additional, Mazzotta, Marco, additional, Di Lauro, Luigi, additional, Amodio, Antonella, additional, Carpano, Silvia, additional, Di Benedetto, Anna, additional, Botti, Claudio, additional, Ferranti, Francesca, additional, Antenucci, Anna, additional, D’Alessandro, Maria Gabriella, additional, Marchetti, Paolo, additional, Tomao, Silverio, additional, Sanguineti, Giuseppe, additional, Giordano, Antonio, additional, Maugeri-Saccà, Marcello, additional, Ciliberto, Gennaro, additional, Conti, Laura, additional, Vici, Patrizia, additional, and Barba, Maddalena, additional

Published
2018
Full Text
View/download PDF

220. Precision diagnostics of Ewing’s sarcoma by liquid biopsy: circulating EWS-FLI1 fusion transcripts

Author

Allegretti, Matteo, primary, Casini, Beatrice, additional, Mandoj, Chiara, additional, Benini, Stefania, additional, Alberti, Laurent, additional, Novello, Mariangela, additional, Melucci, Elisa, additional, Conti, Laura, additional, Covello, Renato, additional, Pescarmona, Edoardo, additional, Milano, Giuseppe Maria, additional, Annovazzi, Alessio, additional, Anelli, Vincenzo, additional, Ferraresi, Virginia, additional, Biagini, Roberto, additional, and Giacomini, Patrizio, additional

Published
2018
Full Text
View/download PDF

222. Circulating cell-free DNA content as blood based biomarker in endometrial cancer

Author

Cicchillitti, Lucia, primary, Corrado, Giacomo, additional, De Angeli, Martina, additional, Mancini, Emanuela, additional, Baiocco, Ermelinda, additional, Patrizi, Lodovico, additional, Zampa, Ashanti, additional, Merola, Roberta, additional, Martayan, Aline, additional, Conti, Laura, additional, Piaggio, Giulia, additional, and Vizza, Enrico, additional

Published
2017
Full Text
View/download PDF

223. A Virus-Like-Particle immunotherapy targeting Epitope-Specific anti-xCT expressed on cancer stem cell inhibits the progression of metastatic cancerin vivo

Author

Bolli, Elisabetta, primary, O'Rourke, John P., additional, Conti, Laura, additional, Lanzardo, Stefania, additional, Rolih, Valeria, additional, Christen, Jayne M., additional, Barutello, Giuseppina, additional, Forni, Marco, additional, Pericle, Federica, additional, and Cavallo, Federica, additional

Published
2017
Full Text
View/download PDF

224. The IKK/NF-κB signaling pathway requires Morgana to drive breast cancer metastasis

Author

Fusella, Federica, primary, Seclì, Laura, additional, Busso, Elena, additional, Krepelova, Anna, additional, Moiso, Enrico, additional, Rocca, Stefania, additional, Conti, Laura, additional, Annaratone, Laura, additional, Rubinetto, Cristina, additional, Mello-Grand, Maurizia, additional, Singh, Vijay, additional, Chiorino, Giovanna, additional, Silengo, Lorenzo, additional, Altruda, Fiorella, additional, Turco, Emilia, additional, Morotti, Alessandro, additional, Oliviero, Salvatore, additional, Castellano, Isabella, additional, Cavallo, Federica, additional, Provero, Paolo, additional, Tarone, Guido, additional, and Brancaccio, Mara, additional

Published
2017
Full Text
View/download PDF

227. Common fragile site tumor suppressor genes and corresponding mouse models of cancer

Author

Drusco, Alessandra, Pekarsky, Yuri, Costinean, Stefan, Antenucci, Anna, Conti, Laura, Volinia, Stefano, Aqeilan, Rami I., Huebner, Kay, and Zanesi, Nicola

Subjects
Physiological aspects, Complications and side effects, Genetic aspects, Research, Chromosome abnormalities -- Complications and side effects -- Research, Cancer -- Genetic aspects -- Research, Tumor suppressor genes -- Physiological aspects -- Research
Abstract

1. Introduction Fragile sites can be defined as heritable-specific loci on human chromosomes that exhibit nonrandom gaps or breaks when chromosomes are exposed to specific cell culture conditions [1]. Classification [...], Chromosomal common fragile sites (CFSs) are specific mammalian genomic regions that show an increased frequency of gaps and breaks when cells are exposed to replication stress in vitro. CFSs are also consistently involved in chromosomal abnormalities in vivo related to cancer. Interestingly, several CFSs contain one or more tumor suppressor genes whose structure and function are often affected by chromosomal fragility. The two most active fragile sites in the human genome are FRA3B and FRA16D where the tumor suppressor genes FHIT and WWOX are located, respectively. The best approach to study tumorigenic effects of altered tumor suppressors located at CFSs in vivo is to generate mouse models in which these genes are inactivated. This paper summarizes our present knowledge on mouse models of cancer generated by knocking out tumor suppressors of CFS.

Published
2011
Full Text
View/download PDF

228. Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin’s lymphomas

Author

Marchesi, Francesco, Pimpinelli, Fulvia, Giannarelli, Diana, Ronchetti, Livia, Papa, Elena, Falcucci, Paolo, Pontone, Martina, Di Domenico, Enea Gino, di Martino, Simona, Laquintana, Valentina, Mandoj, Chiara, Conti, Laura, Cordone, Iole, La Malfa, Antonia, Viggiani, Caterina, Renzi, Daniela, Palombi, Francesca, Romano, Atelda, Pisani, Francesco, Gumenyuk, Svitlana, Di Bella, Ornella, Vujovic, Branka, Morrone, Aldo, Ciliberto, Gennaro, Ensoli, Fabrizio, and Mengarelli, Andrea

Published
2022
Full Text
View/download PDF

229. Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial

Author

Terrenato, Irene, primary, Sperati, Francesca, additional, Musicco, Felice, additional, Pozzi, Anna F., additional, di Turi, Annunziata, additional, Caterino, Mauro, additional, de Lutio di Castelguidone, Elisabetta, additional, Setola, Sergio V., additional, Bellomi, Massimo, additional, Neumaier, Carlo E., additional, Conti, Laura, additional, Cigliana, Giovanni, additional, Merola, Roberta, additional, Antenucci, Anna, additional, Orlandi, Giulia, additional, Giordano, Antonio, additional, Barba, Maddalena, additional, and Canitano, Stefano, additional

Published
2017
Full Text
View/download PDF

230. GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer

Author

Pizzuti, Laura, primary, Sergi, Domenico, additional, Mandoj, Chiara, additional, Antoniani, Barbara, additional, Sperati, Francesca, additional, Chirico, Andrea, additional, Di Lauro, Luigi, additional, Valle, Mario, additional, Garofalo, Alfredo, additional, Vizza, Enrico, additional, Corrado, Giacomo, additional, Tomao, Federica, additional, Rinaldi, Massimo, additional, Carpano, Silvia, additional, Maugeri‐Saccà, Marcello, additional, Conti, Laura, additional, Digiesi, Giovanna, additional, Marchetti, Paolo, additional, De Maria, Ruggero, additional, Giordano, Antonio, additional, Barba, Maddalena, additional, Carosi, Maria A., additional, and Vici, Patrizia, additional

Published
2017
Full Text
View/download PDF

236. Overexpression of syndecan-1, MUC-1, and putative stem cell markers in breast cancer leptomeningeal metastasis: a cerebrospinal fluid flow cytometry study

Author

Cordone, Iole, primary, Masi, Serena, additional, Summa, Valentina, additional, Carosi, Mariantonia, additional, Vidiri, Antonello, additional, Fabi, Alessandra, additional, Pasquale, Alessia, additional, Conti, Laura, additional, Rosito, Immacolata, additional, Carapella, Carmine Maria, additional, Villani, Veronica, additional, and Pace, Andrea, additional

Published
2017
Full Text
View/download PDF

239. AB044. PS02.08: Surgery for TET in the era of translational research: towards a workflow model incorporating the biobank

Author

Alessandrini, Gabriele, primary, Marino, Mirella, additional, Cigliana, Giovanni, additional, Mandoj, Chiara, additional, Di Martino, Simona, additional, Baselice, Simona, additional, Gallo, Enzo, additional, Merola, Roberta, additional, Antenucci, Anna, additional, Antoniani, Barbara, additional, De Bello, Nicoletta, additional, Palmieri, Giovannella, additional, Pescarmona, Edoardo, additional, Conti, Laura, additional, Facciolo, Francesco, additional, and Ciliberto, Gennaro, additional

Published
2017
Full Text
View/download PDF

241. The non-inflammatory role of C1q during Her2/neu-driven mammary carcinogenesis

Author

Bandini, Silvio, primary, Macagno, Marco, additional, Hysi, Albana, additional, Lanzardo, Stefania, additional, Conti, Laura, additional, Bello, Amanda, additional, Riccardo, Federica, additional, Ruiu, Roberto, additional, Merighi, Irene Fiore, additional, Forni, Guido, additional, Iezzi, Manuela, additional, Quaglino, Elena, additional, and Cavallo, Federica, additional

Published
2016
Full Text
View/download PDF

242. Quantitative study of crossregulation, noise and synchronization between microRNA targets in single cells

Author

Bosia, Carla, Sgrò, Francesco, Conti, Laura, Baldassi, Carlo, Cavallo, Federica, Di Cunto, Ferdinando, Turco, Emilia, Pagnani, Andrea, and Zecchina, Riccardo

Subjects
Molecular Networks (q-bio.MN), FOS: Biological sciences, Quantitative Biology - Molecular Networks
Abstract

Recent studies reported complex post-transcriptional interplay among targets of a common pool of microRNAs, a class of small non-coding downregulators of gene expression. Behaving as microRNA-sponges, distinct RNA species may compete for binding to microRNAs and coregulate each other in a dose-dependent manner. Although previous studies in cell populations showed competition in vitro, the detailed dynamical aspects of this process, most importantly in physiological conditions, remains unclear. We address this point by monitoring protein expression of two targets of a common miRNA with quantitative single-cell measurements. In agreement with a detailed stochastic model of molecular titration, we observed that: (i) crosstalk between targets is possible only in particular stoichiometric conditions, (ii) a trade-off on the number of microRNA regulatory elements may induce the coexistence of two distinct cell populations, (iii) strong inter-targets correlations can be observed. This phenomenology is compatible with a small amount of mRNA target molecules per cell of the order of 10-100., Comment: 17 pages, 9 pdf figures, supplementary information included

Published
2015
Full Text
View/download PDF

243. Severe plasma prekallikrein deficiency: Clinical characteristics, novel KLKB1mutations, and estimated prevalence

Author

Barco, Stefano, Sollfrank, Stefanie, Trinchero, Alice, Adenaeuer, Anke, Abolghasemi, Hassan, Conti, Laura, Häuser, Friederike, Kremer Hovinga, Johanna A., Lackner, Karl J., Loewecke, Felicia, Miloni, Erwin, Vazifeh Shiran, Nader, Tomao, Luigi, Wuillemin, Walter A., Zieger, Barbara, Lämmle, Bernhard, and Rossmann, Heidi

Abstract

Severe plasma prekallikrein (PK) deficiency is an autosomal‐recessive defect characterized by isolated activated partial thromboplastin time prolongation. To date, no comprehensive methodologically firm analysis has investigated the diagnostic, clinical, and genetic characteristics of PK deficiency, and its prevalence remains unknown.

Published
2020
Full Text
View/download PDF

244. Fighting breast cancer stem cells through the immune-targeting of the xCT cystine-glutamate antiporter.

Author

Ruiu, Roberto, Rolih, Valeria, Bolli, Elisabetta, Barutello, Giuseppina, Riccardo, Federica, Quaglino, Elena, Merighi, Irene Fiore, Pericle, Federica, Donofrio, Gaetano, Cavallo, Federica, and Conti, Laura

Subjects
CANCER stem cells, HUMORAL immunity, BREAST cancer, METASTASIS
Abstract

Tumor relapse and metastatic spreading act as major hindrances to achieve complete cure of breast cancer. Evidence suggests that cancer stem cells (CSC) would function as a reservoir for the local and distant recurrence of the disease, due to their resistance to radio- and chemotherapy and their ability to regenerate the tumor. Therefore, the identification of appropriate molecular targets expressed by CSC may be critical in the development of more effective therapies. Our studies focused on the identification of mammary CSC antigens and on the development of CSC-targeting vaccines. We compared the transcriptional profile of CSC-enriched tumorspheres from an Her2+ breast cancer cell line with that of the more differentiated parental cells. Among the molecules strongly upregulated in tumorspheres we selected the transmembrane amino-acid antiporter xCT. In this review, we summarize the results we obtained with different xCT-targeting vaccines. We show that, despite xCT being a self-antigen, vaccination was able to induce a humoral immune response that delayed primary tumor growth and strongly impaired pulmonary metastasis formation in mice challenged with tumorsphere-derived cells. Moreover, immunotargeting of xCT was able to increase CSC chemosensitivity to doxorubicin, suggesting that it may act as an adjuvant to chemotherapy. In conclusion, our approach based on the comparison of the transcriptome of tumorspheres and parental cells allowed us to identify a novel CSC-related target and to develop preclinical therapeutic approaches able to impact on CSC biology, and therefore, hampering tumor growth and dissemination. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

245. FK506 bypasses the effect of erythroferrone in cancer cachexia skeletal muscle atrophy

Author

Mina, Erica, Wyart, Elisabeth, Sartori, Roberta, Angelino, Elia, Zaggia, Ivan, Rausch, Valentina, Maldotti, Mara, Pagani, Alessia, Hsu, Myriam Y., Friziero, Alberto, Sperti, Cosimo, Menga, Alessio, Graziani, Andrea, Hirsch, Emilio, Oliviero, Salvatore, Sandri, Marco, Conti, Laura, Kautz, Léon, Silvestri, Laura, and Porporato, Paolo E.

Abstract

Skeletal muscle atrophy is a hallmark of cachexia, a wasting condition typical of chronic pathologies, that still represents an unmet medical need. Bone morphogenetic protein (BMP)-Smad1/5/8 signaling alterations are emerging drivers of muscle catabolism, hence, characterizing these perturbations is pivotal to develop therapeutic approaches. We identified two promoters of “BMP resistance” in cancer cachexia, specifically the BMP scavenger erythroferrone (ERFE) and the intracellular inhibitor FKBP12. ERFE is upregulated in cachectic cancer patients' muscle biopsies and in murine cachexia models, where its expression is driven by STAT3. Moreover, the knock down of Erfeor Fkbp12reduces muscle wasting in cachectic mice. To bypass the BMP resistance mediated by ERFE and release the brake on the signaling, we targeted FKBP12 with low-dose FK506. FK506 restores BMP-Smad1/5/8 signaling, rescuing myotube atrophy by inducing protein synthesis. In cachectic tumor-bearing mice, FK506 prevents muscle and body weight loss and protects from neuromuscular junction alteration, suggesting therapeutic potential for targeting the ERFE-FKBP12 axis.

Published
2023
Full Text
View/download PDF

246. Evaluation of screening method for Bence Jones protein analysis

Author

Basile, Umberto, Gulli, Francesca, Torti, Eleonora, Napodano, Cecilia, Dell'Abate, Maria Teresa, De Santis, Elena, Santini, Stefano Angelo, Conti, Laura, Zuppi, Cecilia, Cigliana, Giovanni, Napodano, Cecilia (ORCID:0000-0002-8720-6284), Santini, Stefano Angelo (ORCID:0000-0003-1956-5899), Zuppi, Cecilia (ORCID:0000-0003-4710-4934), Basile, Umberto, Gulli, Francesca, Torti, Eleonora, Napodano, Cecilia, Dell'Abate, Maria Teresa, De Santis, Elena, Santini, Stefano Angelo, Conti, Laura, Zuppi, Cecilia, Cigliana, Giovanni, Napodano, Cecilia (ORCID:0000-0002-8720-6284), Santini, Stefano Angelo (ORCID:0000-0003-1956-5899), and Zuppi, Cecilia (ORCID:0000-0003-4710-4934)

Abstract

No Abstract available

Published
2016

247. A Magnetic Resonance Imaging‐Chemical Exchange Saturation Transfer (MRI‐CEST) Method for the Detection of Water Cycling across Cellular Membranes.

Author

Di Gregorio, Enza, Papi, Chiara, Conti, Laura, Di Lorenzo, Antonino, Cavallari, Eleonora, Salvatore, Marco, Cavaliere, Carlo, Ferrauto, Giuseppe, and Aime, Silvio

Abstract

Water cycling across the membrane transporters is considered a hallmark of cellular metabolism and it could be of high diagnostic relevance in the characterization of tumors and other diseases. The method relies on the response of intracellular proton exchanging molecules to the presence of extracellular Gd‐based contrast agents (GBCAs). Paramagnetic GBCAs enhances the relaxation rate of water molecules in the extracellular compartment and, through membrane exchange, the relaxation enhancement is transferred to intracellular molecules. The effect is detected at the MRI‐CEST (Magnetic Resonance Imaging ‐ Chemical Exchange Saturation Transfer) signal of intracellular proton exchanging molecules. The magnitude of the change in the CEST response reports on water cycling across the membrane. The method has been tested on Red Blood Cells and on orthotopic murine models of breast cancer with different degree of malignancy (4T1, TS/A and 168FARN). The distribution of voxels reporting on membrane permeability fits well with the cells' aggressiveness and acts as an early reporter to monitor therapeutic treatments. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

248. Microenvironment, Oncoantigens, and Antitumor Vaccination: Lessons Learned from BALB-neuT Mice

Author

Conti, Laura, Ruiu, Roberto, Barutello, Giuseppina, Macagno, Marco, Bandini, Silvio, Cavallo, Federica, and Lanzardo, Stefania

Subjects
Article Subject, skin and connective tissue diseases
Abstract

The tyrosine kinase human epidermal growth factor receptor 2 (HER2) gene is amplified in approximately 20% of human breast cancers and is associated with an aggressive clinical course and the early development of metastasis. Its crucial role in tumor growth and progression makes HER2 a prototypic oncoantigen, the targeting of which may be critical for the development of effective anticancer therapies. The setup of anti-HER2 targeting strategies has revolutionized the clinical outcome of HER2+ breast cancer. However, their initial success has been overshadowed by the onset of pharmacological resistance that renders them ineffective. Since the tumor microenvironment (TME) plays a crucial role in drug resistance, the design of more effective anticancer therapies should depend on the targeting of both cancer cells and their TME as a whole. In this review, starting from the successful know-how obtained with a HER2+ mouse model of mammary carcinogenesis, the BALB-neuT mice, we discuss the role of TME in mammary tumor development. Indeed, a deeper knowledge of antigens critical for cancer outbreak and progression and of the mechanisms that regulate the interplay between cancer and stromal cell populations could advise promising ways for the development of the best anticancer strategy.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results